KALA BIO Embraces a Leadership Change
KALA BIO, Inc. (NASDAQ: KALA), a dedicated clinical-stage biopharmaceutical company focused on eye disease therapeutics, has announced significant changes in its leadership. Mark Iwicki has stepped down from his position as Chief Executive Officer (CEO), with Todd Bazemore, who previously served as the company's President and Chief Operating Officer, stepping in as the interim CEO. This transition reflects KALA's commitment to harnessing its innovative technologies to help patients in need.
Insights from the Former CEO
Mark Iwicki expressed pride in KALA’s advancements, particularly regarding the MSC-S platform and the lead candidate, KPI-012, aimed at treating persistent corneal epithelial defect (PCED). He highlighted the upcoming topline data from the Phase 2b clinical trial, set to be unveiled in the near future. Iwicki looks forward to continuing his involvement as Chair of the Board, supporting the company's mission alongside Bazemore.
The Vision Ahead
Todd Bazemore conveyed his enthusiasm for stepping into this interim role, emphasizing the strength of the foundation laid by Iwicki and their team. He stressed the commitment to developing therapies that aim to preserve vision and enhance quality of life for patients suffering from rare and severe eye conditions. Under his leadership, KALA will continue to focus on the completion of the CHASE trial of KPI-012, a crucial step for the company's ongoing projects.
Todd Bazemore: A Seasoned Executive
Bazemore's extensive background includes over 30 years of experience in various roles across the pharmaceutical industry, addressing everything from ultra-rare diseases to larger primary care challenges. Before joining KALA, he held the position of Executive Vice President and Chief Operating Officer at Santhera Pharmaceuticals (USA), where he was accountable for U.S. operations. His past roles at Dyax Corp. and Sunovion Pharmaceuticals have fortified his capabilities in commercial strategy and execution, equipping him to lead KALA into its next phase of growth.
KALA’s Focus on Innovative Therapies
KALA BIO’s work revolves around the research and commercialization of therapies for severe eye diseases. The company’s lead product, KPI-012, leverages their proprietary mesenchymal stem cell secretome (MSC-S) platform, which contains numerous bioactive components. These components aim to aid corneal healing, a critical factor in treating multiple ocular diseases. The expectations for KPI-012 are substantial, especially as it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, highlighting its potential to make a significant impact in this space.
Looking Toward the Future
As KALA BIO transitions in leadership, the focus remains steadfast on improving patient outcomes through advanced therapies. The company is also exploring the MSC-S platform's potential applications in treating other serious retinal diseases, such as Retinitis Pigmentosa and Stargardt Disease. This proactive strategy represents KALA's dedication to addressing the needs of patients with sight-threatening conditions.
Continuous Development and Innovation
As KALA BIO continues its journey in the biopharmaceutical landscape, it stands committed to developing therapies that meet the pressing needs of patients who suffer from rare eye diseases. The ongoing close partnership between the interim CEO Todd Bazemore and Chair Mark Iwicki is expected to strengthen the organization’s efforts as they push forward with their vision of innovative health solutions.
Frequently Asked Questions
Who is the new interim CEO of KALA BIO?
Todd Bazemore has been appointed as the interim CEO after Mark Iwicki's resignation.
What is KPI-012?
KPI-012 is KALA's lead product candidate designed to treat persistent corneal epithelial defect (PCED).
What experience does Todd Bazemore bring to KALA BIO?
Bazemore has over 30 years of experience in the biopharmaceutical industry, including leadership roles at several companies.
What designations has KPI-012 received from the FDA?
KPI-012 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration.
What is KALA BIO's mission?
KALA BIO's mission is to develop innovative therapies for rare and severe diseases of the eye to improve patient outcomes.
